We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+275.57%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
+$7.44M
Cap. Flow %
5.12%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 48.9%
2 Financials 13.82%
3 Miscellaneous 11.7%
4 Technology 6.61%
5 Consumer Discretionary 5.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FTAI icon
101
FTAI Aviation
FTAI
$20.2B
$334K 0.23%
+2,000
New +$284K
COGT icon
102
Cogent Biosciences
COGT
$6.03B
$323K 0.22%
22,486
-67,725
-75% -$802K
NVO
103
Novo Nordisk
NVO
$206B
$320K 0.22%
+5,759
New +$337K
PRAX icon
104
PUT
Praxis Precision Medicines
PRAX
$9.82B
$319K 0.22%
+230
New +$11.2K
HRMY icon
105
Harmony Biosciences
HRMY
$2.46B
$317K 0.22%
+11,500
New +$396K
OSBC icon
106
Old Second Bancorp
OSBC
$1.31B
$314K 0.22%
+18,182
New +$327K
AMLX icon
107
Amylyx Pharmaceuticals
AMLX
$3.8B
$311K 0.21%
+22,913
New +$216K
DNN icon
108
Denison Mines
DNN
$3.1B
$310K 0.21%
+112,549
New +$249K
SCI icon
109
Service Corp International
SCI
$11.2B
$307K 0.21%
+3,688
New +$294K
RNAM
110
DELISTED
Avidity Biosciences
RNAM
$299K 0.21%
+6,864
New +$277K
INCY icon
111
CALL
Incyte
INCY
$25.7B
$297K 0.2%
+230
New +$18.2K
AGIO icon
112
CALL
Agios Pharmaceuticals
AGIO
$1.98B
$291K 0.2%
546
+230
+73% +$8.65K
DFTX
113
Definium Therapeutics
DFTX
$5.12B
$286K 0.2%
24,282
-12,360
-34% -$115K
VKTX icon
114
CALL
Viking Therapeutics
VKTX
$4.07B
$285K 0.2%
+928
New +$27.7K
LNKB
115
DELISTED
LINKBANCORP
LNKB
$284K 0.19%
+39,782
New +$288K
SMBK icon
116
SmartFinancial
SMBK
$887M
$267K 0.18%
7,485
-12,151
-62% -$435K
VTGN icon
117
VistaGen Therapeutics
VTGN
$10.8M
$267K 0.18%
75,319
-11,500
-13% -$34.4K
ADUS icon
118
Addus HomeCare
ADUS
$2.22B
$267K 0.18%
+2,259
New +$253K
MNKD icon
119
MannKind Corp
MNKD
$1.31B
$265K 0.18%
+49,262
New +$216K
SLSR
120
Solaris Resources
SLSR
$1.36B
$259K 0.18%
40,656
SUPN icon
121
Supernus Pharmaceuticals
SUPN
$2.53B
$247K 0.17%
+5,159
New +$208K
NRG icon
122
NRG Energy
NRG
$25B
$246K 0.17%
+1,520
New +$237K
XNTK icon
123
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.01B
$242K 0.17%
2,317
+346
+18% +$85.2K
HCC icon
124
Warrior Met Coal
HCC
$5.52B
$236K 0.16%
3,716
-12,483
-77% -$713K
BBIO icon
125
CALL
BridgeBio Pharma
BBIO
$14.6B
$236K 0.16%
302
-1
-0.3% -$49

Similar funds

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners deployed $7.44M of net new capital in Q3 2025, opening 137 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 229,544 shares worth $8.19M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was iShares Bitcoin Trust, an estimated $3.43M trimmed.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.